Johnson & Johnson has filled in some of the details of its $55 billion investment in US facilities announced earlier this ...

After UK Health Secretary Wes Streeting sent a letter to the pharma industry, warning that he will withdraw from negotiations ...

Telehealth company Ro has a new spokesperson for its booming GLP-1 business: Serena Williams, the 23-time Grand Slam champion ...

The positive data from the Phase 3 Denali trial showed that NCX 470, a nitric oxide-donating bimatoprost eyedrop formulation, ...

This month’s executive moves in the agency, consultancy, and investor sectors reflect a growing emphasis on strategic ...

Iterum Therapeutics has become the first drugmaker to bring an oral antibiotic in the penem class to market in the US, ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Suzanne Aitken, SVP of managed access at Clinigen, ...

Ionis has won an FDA green light for an RNA-based hereditary angioedema (HAE) treatment, Dawnzera, that can be ...

When it comes to GLP-1 drugs like Ozempic, Wegovy, and Mounjaro there’s a lot to talk about, from the science behind the ...

Twin Health has raised another $53 million to fund its 'digital twin' platform, which provides a model of a patient's unique ...

The Emeryville, California-based biotech has just released topline results from a phase 1/2 head-to-head study comparing its ...

Novo Nordisk has reduced the price of its two semaglutide-based therapies – Ozempic for diabetes and Wegovy for obesity – to ...